Principal Financial Group Inc. Has $12.94 Million Holdings in Immunome, Inc. $IMNM

Principal Financial Group Inc. lifted its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 222.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,104,938 shares of the company’s stock after acquiring an additional 762,147 shares during the period. Principal Financial Group Inc.’s holdings in Immunome were worth $12,939,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in IMNM. Nan Fung Trinity HK Ltd. boosted its stake in Immunome by 7.9% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 592,103 shares of the company’s stock worth $6,934,000 after purchasing an additional 43,253 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of Immunome by 85.0% in the third quarter. New York State Common Retirement Fund now owns 23,500 shares of the company’s stock valued at $275,000 after purchasing an additional 10,800 shares in the last quarter. Stoneridge Investment Partners LLC boosted its position in shares of Immunome by 5.4% during the third quarter. Stoneridge Investment Partners LLC now owns 12,174 shares of the company’s stock worth $143,000 after buying an additional 620 shares during the period. Tema Etfs LLC boosted its position in shares of Immunome by 40.5% during the third quarter. Tema Etfs LLC now owns 162,186 shares of the company’s stock worth $1,899,000 after buying an additional 46,755 shares during the period. Finally, Nisa Investment Advisors LLC grew its holdings in shares of Immunome by 3,513.0% during the third quarter. Nisa Investment Advisors LLC now owns 80,426 shares of the company’s stock worth $942,000 after buying an additional 78,200 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Isaac Barchas sold 383,200 shares of Immunome stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the completion of the transaction, the director owned 2,031,181 shares in the company, valued at approximately $44,157,874.94. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Philip Tsai purchased 10,000 shares of the stock in a transaction on Friday, December 19th. The shares were acquired at an average cost of $20.49 per share, for a total transaction of $204,900.00. Following the transaction, the insider owned 43,300 shares of the company’s stock, valued at approximately $887,217. The trade was a 30.03% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 68,518 shares of company stock valued at $1,453,958 in the last quarter. Company insiders own 7.69% of the company’s stock.

Immunome Trading Up 1.8%

NASDAQ:IMNM opened at $24.93 on Wednesday. The stock has a market capitalization of $2.75 billion, a PE ratio of -8.45 and a beta of 2.32. Immunome, Inc. has a 1-year low of $5.15 and a 1-year high of $27.65. The firm has a fifty day simple moving average of $22.30 and a 200 day simple moving average of $16.29.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Immunome in a research note on Thursday, January 15th. Wall Street Zen raised shares of Immunome from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Guggenheim raised their target price on shares of Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Truist Financial initiated coverage on shares of Immunome in a research note on Monday, December 1st. They issued a “buy” rating and a $36.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Thursday, January 22nd. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $31.00.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.